A new wave of exchange guidance is about to hit from the Center for Consumer Information and Insurance Oversight
That's because a new wave of exchange guidance is about to hit from the Center for Consumer Information and Insurance Oversight (CCIIO), the arm of the federal Department of Health and Human Services (HHS) charged with overseeing the implementation of the exchange provisions included in the Patient Protection and Affordable Care Act (PPACA).
CCIIO is charged with developing rules for the establishment and operation of exchanges, including both the Small Business Health Options Program (SHOP) Exchange and the American Health Benefit Exchange (AHBE)-through which lower-income individuals will be able to access tax credits and cost-sharing subsidies toward the cost of their coverage. In addition, the regulations delve into the unique roles and responsibilities that arise should the feds go into a state to establish an exchange.
Also on the docket are rules around the offering of qualified health plans through such exchanges, protocols for how plan information is relayed to consumers, and the process for determining subsidy and/or refundable tax credit eligibility.
SQUARE AWAY THE DETAILS
With all this in mind, here are some of the important questions payers and providers should ask as they review the regulations:
Answering these questions, and the dozens more that will no doubt arise in the course of the regulation-making process.
This column is written for informational purposes only and should not be construed as legal advice.
Cindy Gillespie is managing director for McKenna Long & Aldridge LLP.
Frank Micciche is senior advisor for McKenna Long & Aldridge LLP.
Conversations With Perry and Friends
April 14th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the Conversations with Perry and Friends podcast. His guest this episode is John Baackes, the former CEO of L.A. Care Health Plan.
Listen
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
Phase 3 Trial of Vertex’s Islet Cell Therapy for Type 1 Diabetes Under Way
April 23rd 2025Zimislecel is an allogeneic stem cell-derived islet cell therapy that could eliminate the need for insulin in those who have type 1 diabetes. Regulatory submissions are expected in 2026, and if approved, would be the second cell therapy for type 1 diabetes.
Read More